Literature DB >> 22435675

Understanding dry eye disease: a managed care perspective.

Richard G Fiscella1.   

Abstract

Dry eye disease (DED) is a multifactorial disorder that results in eye discomfort, visual disturbance, and often ocular surface damage. This supplement to The American Journal of Managed Care discusses the prevalence of DED and the economic burden associated with DED. The etiology and pathophysiology of DED will also be discussed, including disease progression and impact on the patient's quality of life. With greater understanding of the pathophysiology of DED, there are numerous available therapies/strategies for the management of the disorder, ranging from artificial tear substitutes, anti-inflammatory agents, secretagogues, punctal plugs, and systemic immunosuppressives, to surgery. This activity will aim to provide managed healthcare professionals with an understanding of when and how to use these different strategies to reduce morbidity and prevent complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22435675

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  10 in total

Review 1.  Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.

Authors:  Mark S Milner; Kenneth A Beckman; Jodi I Luchs; Quentin B Allen; Richard M Awdeh; John Berdahl; Thomas S Boland; Carlos Buznego; Joseph P Gira; Damien F Goldberg; David Goldman; Raj K Goyal; Mitchell A Jackson; James Katz; Terry Kim; Parag A Majmudar; Ranjan P Malhotra; Marguerite B McDonald; Rajesh K Rajpal; Tal Raviv; Sheri Rowen; Neda Shamie; Jonathan D Solomon; Karl Stonecipher; Shachar Tauber; William Trattler; Keith A Walter; George O Waring; Robert J Weinstock; William F Wiley; Elizabeth Yeu
Journal:  Curr Opin Ophthalmol       Date:  2017-01       Impact factor: 3.761

2.  A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease.

Authors:  Edward J Holland; Jennifer Loh; Marc Bloomenstein; Vance Thompson; David Wirta; Kavita Dhamdhere
Journal:  Clin Ophthalmol       Date:  2022-08-30

3.  Androgen deficiency and dry eye syndrome in the aging male.

Authors:  Patrick M Azcarate; Vincent D Venincasa; William Feuer; Frank Stanczyk; Andrew V Schally; Anat Galor
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-07-03       Impact factor: 4.799

Review 4.  Burning Eye Syndrome: Do Neuropathic Pain Mechanisms Underlie Chronic Dry Eye?

Authors:  Jerry P Kalangara; Anat Galor; Roy C Levitt; Elizabeth R Felix; Ramon Alegret; Constantine D Sarantopoulos
Journal:  Pain Med       Date:  2015-12-24       Impact factor: 3.750

Review 5.  Image-guided evaluation and monitoring of treatment response in patients with dry eye disease.

Authors:  Yureeda Qazi; Shruti Aggarwal; Pedram Hamrah
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-04-04       Impact factor: 3.117

6.  Omega-3 essential fatty acids therapy for dry eye syndrome: a meta-analysis of randomized controlled studies.

Authors:  Aihua Liu; Jian Ji
Journal:  Med Sci Monit       Date:  2014-09-06

7.  TearCare® system extension study: evaluation of the safety, effectiveness, and durability through 12 months of a second TearCare® treatment on subjects with dry eye disease.

Authors:  David Badawi
Journal:  Clin Ophthalmol       Date:  2019-01-22

8.  Ocular surface optimization before cataract surgery.

Authors:  Nandini Venkateswaran; Regina D Luna; Preeya K Gupta
Journal:  Saudi J Ophthalmol       Date:  2022-08-29

9.  A novel system, TearCare®, for the treatment of the signs and symptoms of dry eye disease.

Authors:  David Badawi
Journal:  Clin Ophthalmol       Date:  2018-04-10

10.  Mitochondria-Targeted Antioxidant SkQ1 Prevents Anesthesia-Induced Dry Eye Syndrome.

Authors:  Evgeni Yu Zernii; Olga S Gancharova; Viktoriia E Baksheeva; Marina O Golovastova; Ekaterina I Kabanova; Marina S Savchenko; Veronika V Tiulina; Larisa F Sotnikova; Andrey A Zamyatnin; Pavel P Philippov; Ivan I Senin
Journal:  Oxid Med Cell Longev       Date:  2017-10-12       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.